End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
170 TWD | 0.00% | -0.58% | -8.60% |
Valuation
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Capitalization 1 | 1,111 | 2,832 |
Enterprise Value (EV) 1 | 834.9 | 2,612 |
P/E ratio | -16.5 x | -74.1 x |
Yield | - | - |
Capitalization / Revenue | 85.1 x | 103 x |
EV / Revenue | 63.9 x | 95.2 x |
EV / EBITDA | -15.3 x | -64.6 x |
EV / FCF | - | -63,032,650 x |
FCF Yield | - | -0% |
Price to Book | 3.56 x | 12.8 x |
Nbr of stocks (in thousands) | 15,226 | 15,226 |
Reference price 2 | 73.00 | 186.0 |
Announcement Date | 4/19/24 | 4/19/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net sales 1 | 13.06 | 27.45 |
EBITDA 1 | -54.7 | -40.44 |
EBIT 1 | -55.18 | -41.16 |
Operating Margin | -422.49% | -149.96% |
Earnings before Tax (EBT) 1 | -54.71 | -38.18 |
Net income 1 | -54.71 | -38.18 |
Net margin | -418.88% | -139.1% |
EPS 2 | -4.435 | -2.510 |
Free Cash Flow | - | -41.44 |
FCF margin | - | -150.97% |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 4/19/24 | 4/19/24 |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net Debt 1 | - | - |
Net Cash position 1 | 277 | 220 |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | -41.4 |
ROE (net income / shareholders' equity) | - | -15.8% |
ROA (Net income/ Total Assets) | - | -9.36% |
Assets 1 | - | 407.8 |
Book Value Per Share 2 | 20.50 | 14.60 |
Cash Flow per Share 2 | 21.80 | 14.50 |
Capex 1 | 3.2 | - |
Capex / Sales | 24.52% | - |
Announcement Date | 4/19/24 | 4/19/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-8.60% | 80.17M | |
+5.70% | 32.88B | |
+18.46% | 7.84B | |
+22.71% | 3.95B | |
-17.95% | 3.11B | |
-19.93% | 1.38B | |
-30.65% | 1.21B | |
+4.36% | 933M | |
-34.81% | 911M | |
-26.60% | 829M |
- Stock Market
- Equities
- 6857 Stock
- Financials Acer Medical Inc.